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Review Article
Current Concepts in Bacterial Sexually Transmitted Diseases
Bong Suk Shim
Department of Urology, School of Medicine, Ewha Womans University, Seoul, Korea
Sexually transmitted diseases (STDs) are the most common infectious diseases world-
wide, with over 350 million new cases occurring each year, and have far-reaching 
health, social, and economic consequences. Failure to diagnose and treat STDs at an 
early stage may result in serious complications and sequelae. STDs are passed from 
person to person primarily by sexual contact and are classified into varied groups. Some 
cause mild, acute symptoms and some are life-threatening. They are caused by many 
different infectious organisms and are treated in different ways. Syphilis and gonor-
rhea are ancient afflictions. Now, however, Chlamydia is prevalent and has become 
the most common bacterial STD. Antimicrobial resistance of several sexually trans-
mitted pathogens is increasing, rendering some regimens ineffective, adding to ther-
apeutic problems. A standardized treatment protocol for STDs is recommended to en-
sure that all patients receive adequate treatment. Appropriate treatment of STDs is 
an important public health measure.
Key Words: Chancroid; Chlamydia; Gonorrhea; Sexually transmitted diseases; Syphilis
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial 
License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, 
distribution, and reproduction in any medium, provided the original work is properly cited.
Article History:
received 5 April, 2011
accepted 28 April, 2011
Corresponding Author:
Bong Suk Shim
Department of Urology, School of 
Medicine, Ewha Womans University, 
911-1, Mok-dong, Yangcheon-gu, 
Seoul 158-710, Korea
TEL: +82-2-2650-5157
FAX: +82-2-2654-3682
E-mail: bonstone@ewha.ac.kr
TABLE 1. Pathogens that can be transmitted predominantly by 
sexual intercourse
Bacteria
Viruses
Protozoa, Ectoparasites
Neisseria gonorrhea
Chlamydia trachomatis
Treponema pallidum
Haemophilus ducreyi
Calymmatobacterium
  granulomatis
Ureaplasma urealyticum
Ureaplasma parvum
HIV (types 1 and 2)
Human T cell lymphotropic
  virus type I
Herpes simplex virus type 2
Human papilloma virus
Hepatitis B virus
Molluscum contagiosum virus
Trichomonas vaginalis
Phthirus pubis
INTRODUCTION
Sexually transmitted diseases (STDs) are clinical syn-
dromes caused by pathogens that can be acquired and 
transmitted through sexual activity. The pathogens of 
STDs are bacteria, viruses, fungi, protozoa, and epizoa 
(Table 1). Some pathogens can be sexually transmissible 
even when nonsexual routes of transmission predominate. 
The total number of sexually transmissible pathogens now 
exceeds 35, and each pathogen may have multiple subtypes 
that may have differing clinical manifestations.
The overall incidence and prevalence of bacterial STDs, 
in particular gonorrhea, syphilis, chancroid, and chlamy-
dial infections, have declined since World War II. However, 
the incidence of STDs is still high in developing countries, 
and developing countries are disproportionately affected 
[1,2]. STDs are not spread randomly; unprotected sex with 
an infected partner is by far the most important risk factor 
[1]. The prevalence and distribution of infection depends 
on the behavior of an individual and his or her sex partners. 
Globally, an estimated 12 million people are infected every 
year, and the majority of infections are believed to occur in 
developing countries [3].
If the diagnosis and treatment of STDs are delayed or 
inadequate, the burden of morbidity is significant, espe-
cially among women. The most serious complication in Korean J Urol 2011;52:589-597
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women is pelvic inflammatory disease, primarily asso-
ciated with chlamydia and gonorrhea [4]. Chlamydia, gon-
orrhea, syphilis, and chancroid can be thought of as curable 
STDs, which as a group appear to be short-lived with a high 
transmission probability [5-7], and will be discussed in this 
review article.
CHLAMYDIA
The major pathogen causing nongonococcal urethritis 
(NGU) is Chlamydia trachomatis (C. trachomatis), which 
is estimated to account for 30% to 50% of cases. Chlamydial 
genital infection is the most frequently reported infectious 
disease in STD clinics, and the prevalence is highest in per-
sons aged under 35 years [8-10]. Asymptomatic infection 
is common in women, but approximately 70% of men have 
symptoms such as urethral discharge, dysuria, penile irri-
tation, and signs of epididymo-orchitis or prostatitis.
C. trachomatis is an obligate intracellular parasite and 
cannot be cultured on artificial media [11]. Chlamydial in-
fections of the genital tract are primarily caused by sero-
vars D, E, F, G, H, I, J, and K [11]. Among rectal infections 
in homosexual men, the D and G serovars are particularly 
prevalent [12].
1. Epidemiology
Chlamydial infections of the genital tract have a worldwide 
distribution. The prevalence of chlamydial urethral in-
fection ranges from 3% to 5% of asymptomatic men in gen-
eral medical clinics to 15% to 20% of all men in STD clinics 
[13-15].
Chlamydial infection is a cause of acute proctitis in ho-
mosexual men who practice receptive rectal intercourse, 
and pharyngeal infection with C. trachomatis has been 
demonstrated in 3% to 6% of men and women with a history 
of recent orogenital contact [16,17]. Chlamydial genital in-
fections are closely related to infection with gonorrhea in 
clinical manifestations. Both organisms can infect the 
transitional epithelium of the urethra and can extend to the 
epididymis, the endocervix, the endometrium, salpinx, 
peritoneum, and the rectum [18,19]. They can produce ex-
tensive subepithelial inflammation, epithelial ulceration, 
and scarring.
2. Clinical manifestation
1) Urethritis: C. trachomatis causes 35% to 50% of NGU in 
heterosexual men. Clinically, chlamydia-positive and 
chlamydia-negative NGU cannot be differentiated on the 
basis of signs or symptoms [20,21]. Both usually present 
after an incubation period of 7 to 21 days with dysuria and 
mild-to-moderate whitish or clear urethral discharge. 
Examination reveals no abnormalities other than the dis-
charge in most cases. Most men with asymptomatic chla-
mydial urethral infection exhibit persistent urethral leu-
kocytosis on Gram stains of urethral secretions or persis-
tent pyuria in a first-void urine [22].
The patients with NGU probably acquire gonorrhea and 
chlamydial infection simultaneously, but, because of the 
longer incubation period of C. trachomatis, postgonococcal 
chlamydial urethritis may develop after the gonorrhea is 
treated with an agent that cannot eradicate chlamydia 
[23]. Among men infected with both chlamydia and 
Neisseria gonorrhea (N. gonorrhea) who are treated with 
penicillin, ampicillin, gentamicin, or spectinomycin, 80% 
or more develop symptomatic postgonococcal chlamydial 
urethritis or urethral leukocytosis without symptoms [24].
2) Epididymitis: C. trachomatis causes most cases of idio-
pathic epididymitis in young, heterosexually active males 
[25]. Chlamydial and gonococcal epididymitis are usually 
associated with urethritis caused by C. trachomatis or N. 
gonorrhea in patients who are less than 35 years of age and 
sexually active. Currently, about 70% of acute epididymitis 
in young, sexually active men appears to be attributable 
to chlamydial infection. Chlamydial epididymitis presents 
as unilateral scrotal pain, swelling, tenderness, and fever. 
Men with chlamydial epididymitis improve rapidly with 
tetracycline treatment, supporting the causal role of C. tra-
chomatis [25].
3) Reiter's syndrome: Reiter’s syndrome (urethritis, con-
junctivitis, arthritis, and characteristic mucocutaneous le-
sions) had been related to genital infection with C. tracho-
matis [26].
4) Cervicitis: Many women with chlamydia isolated from 
the cervix have no signs or symptoms of infection; the most 
commonly found symptoms are mucopurulent discharge 
and hypertrophic ectopy [27]. No genital symptoms are spe-
cifically correlated with chlamydial cervical infection. 
Findings on examination suggestive of chlamydial in-
fection include easily induced endocervical bleeding and 
mucopurulent endocervical discharge. The observation of 
purulent yellow or greenish cervical discharge on a cervical 
swab correlates with the presence of chlamydial or gon-
ococcal infection [28].
3. Diagnosis
Because C. trachomatis is an intracellular pathogen, the 
cell culture was the gold standard test for detection for 
years [11]. Owing to the inadequacies, cost, and technical 
difficulties of cell culture, however, many nonculture diag-
nostic tests have been developed for C. trachomatis [11,29]. 
The most widely used of these assays are the direct fluo-
rescent antibody (DFA) and enzyme immunoassay (EIA) 
tests. In general, these tests detect between 60% and 85% 
of infections relative to culture [29,30].
The advantages of the nonculture tests in comparison 
with culture are the ease of use in various settings and low 
cost. However, a noninvasive means of diagnosing chlamy-
dial infection by testing urine has not been realized. The 
sensitivities of these assays with urine have been un-
acceptably low, in the range of 40% to 50%, as compared 
with culture [31]. The specificity of the automated methods 
for the detection of amplified C. trachomatis DNA or RNA 
is consistently above 99% [30]. The polymerase chain re-
action (PCR) in the diagnosis of chlamydial infection has Korean J Urol 2011;52:589-597
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TABLE 2. Recommended regimens for genital chlamydial
infection
Azithromycin 1 g orally in a single dose
OR
Doxycycline 100 mg orally twice a day for 7 days
also been a gold standard. Among males, its sensitivity is 
generally between 87% and 100% [31,32].
4. Treatment
The most active drugs against C. trachomatis in tissue cul-
ture are rifampin and the tetracyclines, followed by macro-
lides, sulfonamides, fluoroquinolones, and clindamycin. 
Penicillin, ampicillin, cephalosporins, and spectinomycin 
for treatment of gonorrhea do not eradicate concomitant 
chlamydial infection, and 7 or more days of treatment with 
tetracyclines or macrolides can eradicate C. trachomatis. 
Fluoroquinolones, such as ofloxacin and levofloxacin show 
similar cure rates, but ciprofloxacin has a relatively high 
failure rate, so it should not be used for the treatment of 
NGU [33,34]. Azithromycin has a half-life of 5 to 7 days and 
excellent intracellular and tissue penetration. It is the only 
single-dose agent for the treatment of chlamydial infection 
(Table 2) [35].
The recommended length of therapy for NGU using tet-
racycline or doxycycline ranges from 7 to 21 days. There is 
as yet no evidence that prolongation of tetracycline or dox-
ycycline therapy beyond 1 week is necessary [36,37]. Sex 
partners are treated concurrently.
Chlamydial infection recurs 3 to 6 weeks after treatment 
in 5% to 10% of cases. Most of the recurrent cases are the 
same immunotype as the primary pathogenic strain, and 
almost all cause recurrent clinical evidence of urethritis.
5. Follow-up
Test-of-cure is not advised unless therapeutic compliance 
is in question, symptoms persist, or reinfection is 
suspected.
GONORRHEA
Gonorrhea is one of the oldest known diseases of humans 
[38]. The major clinical manifestations of gonorrhea in men 
were described in ancient Chinese, Egyptian, Roman, and 
Greek literature as well as in the Old Testament [39]. In 
the fourth and fifth centuries B.C., Hippocrates wrote 
about gonorrhea and he understood that it resulted from 
“the pleasures of Venus.” In the second century, Galen 
coined the word gonorrhea, by which he meant “flow of 
semen.” Neisser demonstrated N. gonorrhea in 1879, and 
Leistikow and Loffler cultured the organism in vitro in 
1882 [40,41].
1. Epidemiology
Gonorrhea is the second most commonly reported bacterial 
STD, and the incidence of new cases of gonorrhea is espe-
cially high in developing countries [42-44]. Most infected 
people, up to 80% of women and 10% of men, are 
asymptomatic. Co-infections with chlamydia and other 
STDs are very common. Among women, gonococcal in-
fections might not produce recognizable symptoms until 
complications such as pelvic inflammatory disease have 
occurred.
The incidence of gonorrhea varies with age. Seventy-five 
percent of cases occur in persons aged under 30 years. The 
incidence of gonorrhea is almost twice as high for sexually 
active adolescents as for sexually active women in the 
20-24-year-old age group [45,46]. Other risk factors are low 
socioeconomic status, early onset of sexual activity, un-
married marital status, and a history of past gonorrhea 
[47]. The incidence of gonorrhea in men who have sex with 
men may still be higher than in exclusively heterosexual 
persons [48].
2. Pathogenesis
N. gonorrhea is the etiologic pathogen of gonorrhea and its 
related clinical syndromes such as urethritis, cervicitis, 
salpingitis, bacteremia, arthritis, and others. N. gonorrhea 
bacteria are gram-negative diplococci, nonmotile and 
non-spore-forming, that characteristically grow in pairs 
with adjacent flattened sides [49].
Humans are the only natural host for gonococci. 
Gonococci survive only a short time outside the human 
body. There is no evidence that natural transmission oc-
curs from toilet seats or similar objects. Because gonorrhea 
is an infection spread by contact, immediate physical con-
tact with the mucosal surfaces of an infected sexual partner 
is required for transmission.
N. gonorrhea initially infects noncornified epithelium, 
most often of the urogenital tract and secondarily of the rec-
tum, oropharynx, and conjunctivae [50]. Ascending genital 
infections such as salpingitis, epididymitis, and bacter-
emia are relatively common and account for most of the se-
rious morbidity due to gonorrhea.
The initial event in gonococcal infection is the adherence 
of N. gonorrhea to mucosal cells in a process mediated by 
pili, Opa, and perhaps other surface proteins [51,52]. 
Progressive mucosal cell damage and submucosal invasion 
are accompanied by a vigorous polymorphonuclear leuko-
cytic response, submucosal microabscess formation, and 
exudation of purulent material into the lumen of the in-
fected organ [53].
3. Clinical manifestation 
Clinical gonorrhea is manifested by a broad spectrum of 
clinical presentations including asymptomatic and symp-
tomatic local infections, local complicated infections, and 
systemic dissemination.
The risk of acquiring urethral infection for a man follow-
ing a single episode of vaginal intercourse with an infected 
woman is estimated to be 20%, rising to an estimated 60% 
to 80% after four exposures [53]. The prevalence of infection Korean J Urol 2011;52:589-597
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in women named as secondary sexual contacts of men with 
gonococcal urethritis has been reported to be 50% to 90% 
[53,54].
The single exposure transmission rate from male to fe-
male is higher than that from female to male because of re-
tention of the infected ejaculate within the vagina. 
Gonorrhea transmission through insertive or receptive 
rectal intercourse presumably is relatively efficient, and 
pharyngeal gonorrhea is readily acquired by fellatio [55]. 
The mean time to development of symptoms is 3.4 days. The 
incidence of asymptomatic urethral gonococcal infection in 
the general population has been estimated at approx-
imately 1% to 3% [56].
In men, gonococcal urethritis usually causes more florid 
signs and symptoms than nongonococcal urethritis and 
has a more abrupt onset, more prominent dysuria, and a 
urethral discharge that is more profuse and more purulent 
in appearance [57]. The incubation period for gonorrhea 
usually is shorter than that of nongonococcal urethritis.
1) Urethral infection in men: The most common manifes-
tation of gonococcal infection in men is an acute anterior 
urethritis. The incubation period ranges from 1 to 14 days 
or even longer. Symptoms develop in most cases within 2 
to 5 days [58].
The predominant symptoms are urethral discharge and 
dysuria. Initially, urethral discharge is scant and mucoid 
or mucopurulent, but the urethral exudate becomes frank-
ly purulent and relatively profuse within 24 hours of onset 
[53]. Approximately 25% of patients develop only a scant 
or minimally purulent exudate, grossly indistinguishable 
from the nongonococcal urethritis [56,59], and a minority 
never develop overt signs [5,56]. Dysuria usually begins af-
ter the onset of discharge. Edema and erythema of the ure-
thral meatus are common. 
Without treatment, the usual course of gonococcal ure-
thritis is spontaneous resolution over a period of several 
weeks, and 95% of untreated patients become asympto-
matic within 6 months. Subsequent asymptomatic car-
riage of N. gonorrhea may occur. Complications of gon-
ococcal urethritis include epididymitis, acute or chronic 
prostatitis, seminal vesiculitis, and infections of Cowper’s 
and Tyson’s glands.
2) Urogenital infection in women: The endocervical canal 
is the primary site of gonococcal infection in women. 
Urethral colonization is present in 70% to 90% of infected 
women [60]. Infection of the periurethral gland or 
Bartholin’s gland ducts is also common. The incubation pe-
riod for urogenital gonorrhea in women is less certain and 
probably more variable than in men, but most who develop 
local symptoms apparently do so within 10 days of infection 
[61]. The most common symptoms are increased vaginal 
discharge, dysuria, intermenstrual uterine bleeding, and 
menorrhagia, each of which may occur alone or in combina-
tion and may range in intensity from minimal to severe 
[62]. Purulent exudate occasionally may be expressed from 
the urethra, periurethral glands, or the Bartholin’s gland 
duct.
3) Rectal infection: The rectal mucosa is a frequent site of 
infection in homosexual men and is infected in 35% to 50% 
of women with gonococcal cervicitis. It is the only site of in-
fection in approximately 5% of women with gonorrhea and 
40% of homosexually active men [63]. Most rectal in-
fections in women occur without acknowledged rectal sex-
ual contact and result from perineal contamination with 
infected cervical secretions. In women, rectal gonorrhea is 
usually asymptomatic. The symptoms of rectal gonococcal 
infection range from minimal anal pruritus, painless mu-
copurulent discharge, or scant rectal bleeding to symptoms 
of overt proctitis, including severe rectal pain, tenesmus, 
and constipation.
4) Pharyngeal infection: Gonococcal infection is trans-
mitted to the pharynx by orogenital sexual contact and is 
more efficiently acquired by fellatio than by cunnilingus. 
Pharyngeal infection occurs in 3% to 7% of heterosexual 
men, 10% to 20% of heterosexual women, and 10% to 25% 
of homosexually active men among patients with gonor-
rhea [64]. Pharyngeal gonococcal infection may cause 
acute pharyngitis or tonsillitis and occasionally is asso-
ciated with fever or cervical lymphadenopathy, but over 
90% of pharyngeal infections are asymptomatic. The occa-
sional occurrence of symptomatic pharyngitis and a possi-
ble increased risk of disseminated gonococcal infection in 
persons with pharyngeal gonorrhea are countered by the 
usual absence of symptoms and a spontaneous cure rate 
that approaches 100% within 12 weeks of infection [64,65].
4. Diagnosis
Specific diagnosis of infection with N. gonorrhea can be per-
formed by testing endocervical, vaginal, urethral, or urine 
specimens. Culture, nucleic acid hybridization tests, and 
nucleic acid amplification tests (NAATs) are available for 
the detection of genitourinary infection with N. gonorrhea 
[66].
The standard diagnostic procedure for men with sympto-
matic urethritis is the Gram stain, because of its high spe-
cificity (＞99%) and sensitivity (＞95%) [67]. However, in 
asymptomatic men or in women with genital infection, the 
Gram stain is less useful, because of lower sensitivity. 
Gram stain of endocervical specimens, pharyngeal speci-
mens, or rectal specimens is not sufficient to detect in-
fection and therefore is not recommended.
  NAATs allow testing of the widest variety of specimen 
types including endocervical swabs, vaginal swabs, ure-
thral swabs in men, and urine from both men and women. 
The sensitivity of NAATs for the detection of N. gonorrhea 
in genital and nongenital anatomical sites is superior to 
culture but varies by NAAT type [68]. All persons found to 
have gonorrhea should also be tested for other STDs, in-
cluding chlamydia, syphilis, and HIV [69].
5. Treatment 
By the late 1980s, penicillins and tetracyclines were no lon-
ger recommended for gonorrhea therapy. Because of the 
high prevalence of penicillinase producing N. gonorrhea Korean J Urol 2011;52:589-597
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TABLE 3. Recommended regimens for gonococcal infection
Ceftriaxone 250 mg IM in a single dose
OR
Cefixime 400 mg orally in a single dose
OR
Spectinomycin 2 g IM in a single dose
(PPNG), in 1981, spectinomycin had been adopted as the 
drug of choice for gonorrhea therapy. In 1987, clinically sig-
nificant chromosomally mediated resistance to spectino-
mycin was reported and the prevalence of spectinomy-
cin-resistant N. gonorrhea increased [70]. In 1993, fluo-
roquinolones were recommended for the therapy of 
gonorrhea. These were effective in single-dose, oral regi-
mens and were unrelated to β-lactam antibiotics. By 2007, 
however, the prevalence of gonococcal strains with dimin-
ished fluoroquinolone susceptibility had exceeded 5% [71].
Now ceftriaxone and other third-generation cepha-
losporin antibiotics have become the most reliable sin-
gle-dose regimen for the treatment of gonorrhea. The dose 
of ceftriaxone currently recommended for therapy of un-
complicated gonorrhea is a single intramuscular injection 
of 250 mg. It is also highly effective for rectal and phar-
yngeal gonorrhea. Cefixime, an orally absorbed cepha-
losporin for N. gonorrhea that is similar to ceftriaxone, pro-
vides a useful oral alternative to parenteral ceftriaxone. A 
single 2 g dose of azithromycin has also been found to be 
effective for gonorrhea therapy [72], although gastro-
intestinal side effects (nausea, vomiting) are relatively 
common with this regimen and there is reason for concern 
for the potential for N. gonorrhea to rapidly develop clin-
ically significant resistance (Table 3).
6. Follow-up 
Patients diagnosed with uncomplicated gonorrhea who are 
treated with any of the recommended or alternative regi-
mens do not need a test-of-cure, because all recommended 
regimens have cure rates that approach 100%. Patients 
who have symptoms that persist after treatment should be 
evaluated by culture for N. gonorrhea, and any gonococci 
isolated should be tested for antimicrobial susceptibility.
SYPHILIS
Syphilis is a systemic disease caused by Treponema pallid-
um and is the most fascinating disease of humans. On the 
basis of clinical findings, the disease has been divided into 
a series of stages, such as primary infection (ulcer or chan-
cre), secondary infection (skin rash, mucocutaneous le-
sions, and lymphadenopathy), neurologic infection 
(cranial nerve dysfunction, meningitis, stroke, altered 
mental status, loss of vibration sense, and auditory or oph-
thalmic abnormalities), tertiary infection (cardiac or 
gummatous lesions), and latent infections of unknown 
duration.
1. Pathogenesis
The  Treponema species are members of the family 
Spirochaetaceae within the order Spirochaetales. All mem-
bers of the Spirochaetales  are characterized by spiral 
shape, corkscrew motility, and the existence of periplasmic 
flagella [73].
The disease is usually acquired by sexual contact, with 
the exception of congenital syphilis. Transmission by sex-
ual contact requires exposure to moist mucosal or cuta-
neous lesions of primary or secondary syphilis. Patients 
with untreated disease may apparently recover only to re-
lapse over a period of up to 2 years. The rate of acquisition 
of syphilis from an infected sexual partner during a single 
sexual contact has been estimated at about 30% [74].
2. Epidemiology
The incidence of syphilis is higher in many other areas of 
the world than in Western Europe and the United States. 
About 4 million new cases occur yearly in each of Southeast 
Asia and sub-Saharan Africa [75].
3. Diagnosis
Darkfield examinations and tests to detect T. pallidum in 
lesion exudate or tissue are the definitive methods for diag-
nosing early syphilis [76]. A presumptive diagnosis of syph-
ilis is possible with the use of two types of serologic tests: 
1) nontreponemal tests, including Venereal Disease Rese-
arch Laboratory (VDRL) and Rapid Plasma Reagin (RPR), 
and 2) treponemal tests, including fluorescent treponemal 
antibody absorption tests, the Treponema pallidum Hema-
gglutination Assay, various EIAs, and chemiluminescence 
immunoassays. The use of only one type of serologic test 
is insufficient for diagnosis, because each type of test has 
limitations, including the possibility of false-positive 
results. False-positive nontreponemal test results can be 
associated with various medical conditions unrelated to 
syphilis, including autoimmune conditions, older age, and 
injection-drug use [76,77]. Therefore, persons with a re-
active nontreponemal test should receive a treponemal test 
to confirm the diagnosis of syphilis.
Nontreponemal test antibody titers may correlate with 
disease activity, and the results should be reported quanti-
tatively [76]. A fourfold change in titer, equivalent to a 
change of two dilutions (e.g., from 1 : 16 to 1 : 4 or from 1 : 8 
to 1 : 32), is considered necessary to demonstrate a clin-
ically significant difference between two nontreponemal 
test results that were obtained by using the same serologic 
test. Sequential serologic tests in individual patients 
should be performed by using the same testing method, 
preferably by the same laboratory. The VDRL and RPR are 
equally valid assays. Nontreponemal test titers usually de-
cline after treatment and might become nonreactive with 
time.
Most patients who have reactive treponemal tests will 
have reactive tests for the remainder of their lives, regard-
less of treatment or disease activity [78]. Treponemal test 
antibody titers should not be used to assess treatment Korean J Urol 2011;52:589-597
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TABLE 4. Recommended regimens for syphilis
Primary syphilis, secondary syphilis, early latent syphilis
    Benzathine penicillin G 2.4 million units IM in a single dose
Late latent syphilis, latent syphilis of unknown duration, 
  tertiary syphilis
    Benzathine penicillin G 7.2 million units total,
      administered as 3 doses of 2.4 million units IM each at 
      1-week intervals
Neurosyphilis
    Aqueous crystalline penicillin G 18-24 million units
      per day, administered as 3-4 million units IV every
      4 hours or continuous infusion, for 18-21 days
response.
4. Clinical manifestation
1) Primary syphilis: The initial lesion of syphilis is a papule 
that appears at the site of venereal contact, from 10 to 90 
days, an average of 3 weeks after exposure. The papule 
grows to a size of 0.5 to 1.5 cm in diameter and after about 
a week ulcerates, producing the typical chancre of primary 
syphilis, a round or slightly elongated ulcer, 1 to 2 cm 
across, with an indurated margin. The ulcer has a clear 
base, without an exudate. Primary syphilitic chancres 
most frequently occur in the genital, perineal, or anal area, 
but any part of the body can be affected. Most chancres are 
found on the penis of men and on the labia, fourchette, and 
cervix of women. In the absence of treatment, syphilitic 
chancres heal spontaneously within 3 to 6 weeks. Modest 
enlargement of inguinal lymph nodes, frequently bi-
laterally, is observed.
Differentiating a syphilitic chancre from chancroid, the 
lesion caused by Haemophilus ducreyi, may be impossible 
on clinical grounds, although a great degree of tenderness, 
a jagged border, a yellow exudate, or striking inguinal lym-
phadenopathy, especially if the overlying skin is thin and 
shiny, is suggestive of chancroid [79].
2) Secondary syphilis: Secondary syphilis is a systemic 
disease. Within a few weeks or months, a variable systemic 
illness develops, characterized by low-grade fever, ma-
laise, sore throat, headache, adenopathy, and cutaneous or 
mucosal rash [80].
The initial finding in disseminated syphilis is an evan-
escent copper-colored macular rash. A few days later, a 
symmetric papular eruption appears, involving the entire 
trunk and the extremities, including the palms of the hands 
and soles of the feet. The papules are red or reddish brown, 
discrete, and usually 0.5 to 2 cm in diameter. They are gen-
erally scaly, although they may be smooth, follicular, or, 
rarely, pustular. Hypo- or hyperpigmentation may be seen. 
Alopecia occurs in some cases. Mucosal lesions, either 
small, superficial, ulcerated areas with grayish borders 
that resemble painless aphthous ulcers or larger gray pla-
ques, are also common. Large, raised, whitish or gray con-
dyloma lata results from the effects of local skin breakdown 
in warm, moist areas, most frequently, the axilla and groin.
3) Tertiary syphilis: There may be an interval of 1 to over 
20 years from the acute infection to clinical onset of the late 
or tertiary stages of disease, long after the lesions of early 
syphilis have been forgotten. By definition, persons with 
historical or serological evidence of syphilis who have never 
received treatment for this disease and who have no clinical 
manifestations are said to have latent syphilis.
Tertiary syphilis occurs in many clinical syndromes, 
most conveniently divided into three groups: neurosy-
philis, cardiovascular syphilis, and late benign syphilis. 
Abnormalities in the cerebrospinal fluid have been noted 
in 13% of patients with untreated primary syphilis and in 
25% to 40% of patients with untreated secondary syphilis 
[81].
Syphilis of the cardiovascular system becomes clinically 
manifest after a latent period of 15 to 30 years. Most pa-
tients are between 40 and 55 years of age at onset, and men 
are affected three times as often as women. Late benign 
syphilis or gumma is a proliferative granulomatous in-
flammatory process that may destroy affected tissues. 
Most lesions occur in the skin and the bones [82].
5. Treatment 
Penicillin G, administered parenterally, is the preferred 
drug for treating all stages of syphilis. The preparation 
used, the dosage, and the length of treatment depend on 
the stage and clinical manifestations of the disease (Table 
4) [83,84].
The Jarisch-Herxheimer reaction is an acute febrile re-
action frequently accompanied by headache, myalgia, fe-
ver, and other symptoms that usually occur within the first 
24 hours after the initiation of any therapy for syphilis [85]. 
Antipyretics can be used to manage symptoms, but they 
have not been proven to prevent this reaction.
1) Primary or secondary syphilis: A single dose of 2.4 mil-
lion units of benzathine penicillin appears to produce a clin-
ical cure of primary or secondary syphilis. For patients who 
are unable to take penicillin, ceftriaxone 1 g intravenously 
or intramuscularly every day for 10 days should provide 
identical results [86]. Tetracycline 500 mg four times daily 
or doxycycline 100 mg twice daily for 14 days may be just 
as effective [87]. Azithromycin has been used successfully 
to treat syphilis and has the advantage of apparently being 
curative in primary and secondary stage illness after a sin-
gle oral dose of 1 or 2 g [88]. Patients who fail therapy, as 
measured by clinical relapse or a fourfold or greater rise in 
RPR titers, should be retreated, usually with benzathine 
penicillin in a dose of 2.4 million units IM weekly for 3 weeks 
[89].
Clinical and serologic evaluation should be performed 6 
months and 12 months after treatment [90]. Failure of non-
treponemal test titers to decline fourfold within 6 to 12 
months after therapy for primary or secondary syphilis 
might be indicative of treatment failure [83].
2) Latent syphilis: Because latent syphilis is not trans-
mitted sexually, the objective of treating patients with this 
stage of disease is to prevent complications. A single in-Korean J Urol 2011;52:589-597
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TABLE 5. Recommended regimens for chancroid
Azithromycin 1 g orally in a single dose
OR
Ceftriaxone 250 mg IM in a single dose
OR
Ciprofloxacin 500 mg orally twice a day for 3 days
OR
Erythromycin base 500 mg orally three times a day for 7 days
jection of benzathine penicillin, 2.4 million units, should be 
given in early latent syphilis (less than 1 year), but three 
injections should be given at weekly intervals for late latent 
syphilis or syphilis of unknown duration [91].
The response of latent syphilis to therapy is difficult to 
assess. Because the patient is free of symptoms, the only 
possible response is a change in serologic test results. The 
RPR titer often remains unchanged, or it may decline, but 
it usually does not return to negative. Rising titers suggest 
therapeutic failure, in which case a cerebrospinal fluid ex-
amination must be done and the patient must receive ei-
ther a repeat of the initial therapy or a more aggressive 
therapy.
CHANCROID
Haemophilus ducreyi is a gram-negative coccobacillus that 
causes chancroid, which is characterized by painful genital 
ulcers and inguinal lymphadenitis [92]. Erythematous 
papules form at each entry site within several hours to days 
and evolve into pustules in 2 to 3 days. Papules and pus-
tules are usually not painful. After a few days to 2 weeks, 
the pustules ulcerate and patients typically have 1 to 4 
painful ulcers [92,93].
The combination of a painful genital ulcer and tender 
suppurative inguinal adenopathy suggests the diagnosis 
of chancroid [94]. Culture and PCR-based tests are the cor-
nerstones of diagnostic testing.
Chancroid is successfully treated with macrolides, qui-
nolones, and third-generation cephalosporins (Table 5) 
[93]. Effective regimens are a single dose of azithromycin 
1 g orally or ceftriaxone 250 mg intramuscularly, cipro-
floxacin 500 mg orally twice a day for 3 days, or eryth-
romycin base 500 mg orally three times a day for 7 days. 
In general, most of these regimens have cure rates greater 
than 90% [95,96].
CONCLUSIONS
Chlamydia, gonorrhea, syphilis, and chancroid can be 
thought as curable bacterial STDs. Appropriate diagnosis 
and treatment of STDs is an important public health 
measure.
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